XNAS · Healthcare · Biotechnology
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-05 | Q1 2026 | -0.65 | 0.05 | +107.69% | $56.4M | ✅ Beat | +4.63% | +0.75% | — |
| 2026-02-25 | Q4 2025 | -0.54 | -0.69 | -27.78% | $7.4M | ❌ Miss | -0.22% | +8.87% | +13.63% |
| 2025-11-06 |
| Q3 2025 |
| -0.62 |
| -0.62 |
| +0.00% |
| $4.7M |
| ➖ Inline |
| — |
| — |
| — |
| 2025-08-06 | Q2 2025 | -0.53 | -0.55 | -3.77% | $5.5M | ❌ Miss | -2.53% | +5.30% | +12.37% |
| 2025-02-21 | Q4 2024 | 1.03 | 1.98 | +92.23% | $170.6M | ✅ Beat | -7.10% | -2.99% | +35.56% |
| 2024-11-07 | Q3 2024 | -0.63 | -0.54 | +14.29% | $4.7M | ✅ Beat | -2.90% | -13.80% | -14.93% |
| 2024-08-06 | Q2 2024 | -0.60 | -0.50 | +16.67% | $4.2M | ✅ Beat | -1.16% | +11.32% | +16.05% |
| 2024-05-07 | Q1 2024 | 2.51 | 3.26 | +29.88% | $255.0M | ✅ Beat | +5.12% | +14.81% | +31.91% |
Showing last 8 quarters.